Do you have a patient who is eligible to take part in a phase three study for pregnancies at risk for severe Haemolytic Disease of the Foetus and Newborn (HDFN).
This rare and potentially life-threatening condition can occur when the blood types of the mother and foetus are incompatible.
Azalea’s clinical trial is designed to evaluate the efficacy of an investigational product in pregnancies at risk for severe HDFN. It is currently open for recruitment at Liverpool Hospital.
Participation criteria and further information can be found on clinicaltrials.gov.
Additional eligibility criteria will be assessed by the study team.
For more information, you can contact:
- Professor John Smoleniec on 0419 989 162 or by email at John.Smoleniec@health.nsw.gov.au
- clinical trial coordinator Marie-Elle Ajaka on 0491 157 469 or marieelle.ajaka@health.nsw.gov.au
- leave a message for the Feto-Maternal Unit at Liverpool Hospital on 8738 5631
This article appeared in Practice Pulse on Wednesday, 29 April 2026. If you are a GP, practice nurse or practice manager in South Western Sydney and do not get the weekly Practice Pulse email, speak to your Practice Support Officer.